Member Info for HotblackDesiato

Well who saw that coming? I mean apart from those who dumped shares over the last few days. If it turns out to be spouses then heads should roll.

That aside, I presume the CRO will have insurance and as it's their 'problem' they will be liable for costs unless there's some small print in the contract giving them a get out clause if this sort of thing were to happen.

I don't see why SAR should be out of pocket as the CRO are the responsible party.

Hi JB - the BoD will never publicly give a valuation for the whole company. IF a pharma were looking at a T/O and based on their own research thought our compounds were worth, say, £2bn and our BoD have said "we're worth £1bn" then we all know what would happen next.

All the BoD can do is point to deals made for similar compounds e.g. drug X was sold/on-licensed for £Y at a similar stage of development.

In the Edison video JR said 1801 has a very clean profile. Once all the tox data is signed off later in the year and ReceptorAi have completed their work we should be able to guage our value based on competitors' deals. IF 1801 has a best in class tox profile then the sp will follow.

Hi JB - and if I had 1p for every time someone didn't do their own research I wouldn't have to be invested here.

I think you've had one martini too many, Bond.

https://www.investopedia.com/terms/c/closeperiod.asp

Just further to this story, there's an article in the latest issue of Money Week on GSK that notes -

'Luke Miels will start “with the historical baggage of slow revenue growth and a low valuation”, says Neil Unmack on Breakingviews. He also faces the problem that some of GSK’s principal drugs, especially HIV treatment dolutegravir, are only a few years away from losing patent protection. President Donald Trump’s efforts to drive down drug prices will also affect sales. So the logical move for the new boss is to start thinking about buying some companies, a task facilitated by GSK’s “relatively clean balance sheet”.'

He starts his job in January, just in time for the 1801/BBB data to appear.

I hope SP has already been on the phone...

We're clearly still in the very early stages of discovery so I think once ReceptorAi gets back to us with their full findings, at that point I'd expect more of a fanfare. For the moment all we can say is something might have potential. A computer model demonstrating how our drug could cross the BBB will get the interest of larger players.

Regards.

Hi Andy - getting older by the day! I'm not over the hill just yet but I want SAR to come up trumps sooner rather than later as I'd like to be a millionaire while I can still fully enjoy it!

In response to Edison's article (link below), SP tweeted on23rd Sept tweet, "Fascinating read from the Edison healthcare team - looking forward to the work in CNS by @Sareumplc being featured soon!"

https://www.edisongroup.com/thematic/the-cns-renaissance-innovations-are-reshaping-neurological-therapies/BM-2199/

So the interview was to specifically look at the CNS side of our compounds, nothing more.

Hi Aber - we couldn't begin the collab with ReceptorAi without having the funds already in place so I'm presuming the recent warrant uptakes have eased the financial strain the work might otherwise have applied to our resources.

I think it's been a very smart move to ensure we own the CNS compounds 100% as SP alludes at 8:50 in the video, royalty stacking isn't attractive when you want to either on-license or sell the whole business.

With 737 being the only part-owned compound, we'll be in a very nice position if someone wants the whole shebang.

Yes, video appears to work now.

https://www.youtube.com/watch?v=52ypedWqm00

At the 5:18 mark, "1801 demonstrates a really clean safety profile" - so, letting the cat out the bag from the extended tox trial?

Sounds like lots of positive news to come by the end of the year.

Hi Num4 - I think there's a widespread YT problem as no videos appear to be available at the moment on any channel.

Nothing showing here yet but I don't know if there's any legal obligation requiring a company to be included -

https://www.lse.co.uk/share-prices/financial-diary.html?selected-date=01-Oct-2025&mode=month

Hi NavM - assuming the BoD hang on until the end of the month for the final results, I'd expect buying to pick up after mid-month. Some encouraging noises from ReceptorAi wouldn't go amiss ahead of the report along with confirmation that TM is still active and not on gardening leave.

Meh, when we finally reach lift-off it'll be straight up and none of this rollercoaster malarky.

Scream if you want to go faster.

The Cairngorms in October are good for landscape photography but not much else! Hope the weather isn't too wet for you.

Hi PCS - it'd be nice to think 737 still has legs and we simply haven't heard anything about it recently as it's part of a larger deal. Everything is dovetailing towards the year end for news on all fronts. There are too many research papers utilising 737 to good effect that I find it hard to imagine no one wants it. If 1801 has a class-leading tox profile and ReceptorAi comes up with something exciting then who knows where we'll be within the next 6mths? The sp might even establish itself over 30p!

A final AGM might actually be on the cards this time round.

Interesting post, Krone. Page 36 in the link below for anyone interested -

https://www.sec.gov/Archives/edgar/data/1290149/000119312522134756/d571460dprem14a.htm

J&J's oral drug icotrokinra looks like taking a chunk of sotyktu's market, "Analysts at Jefferies estimated last month that icotrokinra could bring in peak sales of $7.5 billion in the U.S. across various indications, with another $2.1 billion coming from international sales."

https://www.fiercebiotech.com/biotech/jjs-il-23-drug-defeats-reigning-champ-sotyktu-phase-3-psoriasis-trial

Icontrokinra's further down the road than 1801 but note it only inhibits IL-23 whereas 1801 gives greater coverage than single inhibitors. This means 1801 has the potential for increased efficacy across several autoimmune targets. More targets = more revenue. Ker-ching.

Excellent find, Krone. I hope SP is cracking the whip to ensure JR is banging out the related patents. I think CNS/BBB drugs could be the next big thing.

Last year the final results were posted on 29th Oct. and on the 9th in 2023 so we're looking at maybe anywhere from 2 - 5weeks for the report.

I wouldn't be surprised if punters took a chance with their money elsewhere for a week or so but they might miss the boat if a deal appears out of nowhere or results get published early in the month.